research Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span
Polycystic ovary syndrome costs the U.S. over $4 billion a year, mainly from treating related health issues.
Search
for
Sort by
Research
240-270 / 1000+ results 
research Genome-wide Target Enrichment-aided Chip Design: a 66 K SNP Chip for Cashmere Goat
Researchers developed a cost-effective 66 K SNP chip for cashmere goats that is accurate and useful for genetic studies.
research P095 The Very Interesting Small Bowel Lesions of Cronkhite-Canada Syndrome
Small bowel lesions in Cronkhite-Canada syndrome persist despite steroid treatment.
research FINASTERIDE FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
Finasteride may help treat chronic CSC, improving vision.
research Cost-minimization Analysis of 2 Drug Therapy Projects Including Traditional Chinese Medcines and Chemical Medcines in BPH Patients
Qianliekang and liuweidihuangwan are cheaper for BPH treatment than finasteride and tamsulosin.
research Cronkhite-Canada Syndrome Associated With Superficial Esophageal Carcinoma: A Case Report and Literature Review
Regular endoscopic checks are crucial for Cronkhite-Canada syndrome patients to catch potential cancers early.
research Patient characteristics associated with all-cause healthcare costs of alopecia areata in the United States
Middle-aged patients, those in the Northeast, with comprehensive insurance, extensive hair loss, or additional health issues, and young or older females face higher alopecia areata medical costs.
research Cronkhite-Canada syndrome: A case report and literature review
Cronkhite-Canada syndrome is rare, has a poor prognosis, and requires early diagnosis and ongoing treatment.
research Cronkhite-Canada syndrome: A rare disease presenting with dermatological and gastrointestinal manifestations
A patient with Cronkhite-Canada syndrome improved with nutritional support and steroids, but early diagnosis is key due to high mortality.
research A Case of Cronkhite-Canada Syndrome Presenting with Hematochezia
Cronkhite-Canada syndrome can cause multiple gastrointestinal polyps and various physical symptoms.
research Health Insurance Coverage Mandates: Colorectal Cancer Screening in the Post-ACA Era
Reducing out-of-pocket costs increased colorectal cancer screenings.
research Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis
Alopecia areata in Saudi Arabia is costly, mainly due to lost productivity and drug costs.
research Central Centrifugal Cicatricial Alopecia: A Survey of Treatment Practices Among Dermatology Residents and Attending Physicians
There is no standard treatment for CCCA, and practices vary widely.
research Shared decision-making in central centrifugal cicatricial alopecia
Patients with central centrifugal cicatricial alopecia benefit from shared decision-making with their doctors.
research DTC pharmaceutical advertising: the debate’s not over
The debate on direct-to-consumer pharmaceutical ads continues, with consumers finding them educational and doctors concerned about their impact on patient relationships and medication understanding.
research Association of breast and colorectal cancer in patients with central centrifugal cicatricial alopecia: A retrospective, cross-sectional pilot study
Patients with central centrifugal cicatricial alopecia may have a higher risk of breast and colorectal cancer.
research 논문 : 프로스카 정(피나스테리드 5 mg)에 대한 푸로케어 정의 생물학적동등성
Procare is bioequivalent to Proscar.
research Price Discrimination Across Indications in the Pharmaceutical Industry: The Case of Finasteride
Proscar and Propecia, two drugs with the same ingredient but different dosages, have different prices, showing price discrimination in the pharmaceutical industry.
research Evaluating safety and ethical implications of androgenetic alopecia treatments: a comparison of direct-to-consumer platforms and dermatologist visits
Dermatologist visits offer safer and more ethical treatment for hair loss than direct-to-consumer platforms.
research PD14-05 ECONOMIC IMPLICATIONS OF UROLOGIST PRESCRIPTION PRACTICES AMONG MEDICARE PART D BENEFICIARIES
Using more low-cost and generic drugs could save Medicare Part D a lot of money.
research Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial
Oral contraceptives with CPA improve overall quality of life for women with PCOS.
research POINT OF CARE W RADIOLOGII
Point of Care in radiology speeds up diagnosis and treatment by performing tests where the patient is.
research Minority hair tax: pricing bias in haircare products
Coily/curly hair products cost more than straight hair products, highlighting a need for fair pricing.
research Insurers Give Short Shrift to ASCO Pathways Recommendation
Insurers opposed ASCO's recommendation for a single cancer care pathway program.
research A global analysis of CNVs in Chinese indigenous fine-wool sheep populations using whole-genome resequencing
The study mapped genetic variations in sheep, linking them to traits like milk production and growth.
research Dietary Supplement and Prescription Omega-3 Fatty Acid Products Use among Iraqi Consumers in Kirkuk City
Consumers in Kirkuk City use both prescription and nonprescription omega-3 products, but need better understanding of their differences.
research Hair Loss and Polyposis in Cronkhite-Canada Syndrome
Prednisone treatment helped a woman with Cronkhite-Canada syndrome recover from hair loss and digestive issues.
research Polycystic ovary syndrome
Early diagnosis and treatment of PCOS are crucial to reduce health risks and costs.
research 309 DOES VARIATION IN EITHER AGE AT START OF THERAPY OR DURATION OF THERAPY MAKE CHEMOPREVENTION WITH FINASTERIDE COST-EFFECTIVE?
Starting finasteride at age 65 and continuing until age 80 is the most cost-effective strategy for prostate cancer prevention.
research Doing Well by Doing Good: The Benevolent Halo of Corporate Social Responsibility
Corporate social responsibility can improve consumer ratings of product performance, especially when the company is seen as benevolent and consumers aren't experts on the product.